Home › Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA (pembrolizumab) for the Treatment of Multiple Types of Cancer
 

Keywords :   


Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA (pembrolizumab) for the Treatment of Multiple Types of Cancer

2016-06-29 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & CAMBRIDGE, Mass. Collaboration Combines Mercks Leadership in Immuno-Oncology with Modernas Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879or Moderna Media:Liz Melone, 617-256-6622orInvestors:Maren Winnick, 617-674-5297 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of types multiple treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »